Physician Assistant · Champaign, IL
NPI
1922159110
Since 2007
Specialty
Physician Assistant
Code 363A00000X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
1701 W. Curtis Road, Dermatology
Champaign, IL, 61822
Phone (217) 365-6204
Groups this clinician bills Medicare through
Medicare paid, 2024
$100K
5,286 services
Medicare patients, 2024
1,089
Average age 73
Drug cost, 2024
$4.1M
3,243 prescriptions
Company payments, 2025
$3,496
From 20 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Jeremy Medler was code 17003 (destruction skin lesion), 2,525 times for 387 patients. In total Jeremy Medler billed 5,286 services in 20 codes, and Medicare paid $100K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2014-05-07.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 17003 Destruction Skin Lesion | Office | 2,525 | 387 | $1.09 | $2,743 |
| 99213 Office E&M - Established | Office | 1,174 | 776 | $36.83 | $43K |
| 17000 Destruction Skin Lesion | Office | 574 | 428 | $29.25 | $17K |
| 11102 Skin Biopsy | Office | 254 | 233 | $16.57 | $4,208 |
| 99214 Office E&M - Established | Office | 212 | 173 | $48.56 | $10K |
| 99203 Office E&M - New | Office | 137 | 137 | $45.96 | $6,296 |
| 17004 Destruction Skin Lesion | Office | 136 | 88 | $52.00 | $7,073 |
| 11103 Skin Biopsy | Office | 99 | 68 | $12.68 | $1,255 |
| 99204 Office E&M - New | Office | 52 | 52 | $69.24 | $3,600 |
| 17110 Destruction Skin Lesion | Office | 37 | 37 | $37.96 | $1,405 |
| 99202 Office E&M - New | Office | 32 | 32 | $21.83 | $699 |
| 11104 Skin Biopsy | Office | 15 | 13 | $28.63 | $429 |
| 17111 Destruction Skin Lesion | Office | 14 | 12 | $45.85 | $642 |
By year: 2022 $119K for 6,691 services; 2023 $116K for 6,225 services; 2024 $100K for 5,286 services.
Medicare prescription drug claims, 2024
In 2024, the drug Jeremy Medler prescribed most often to Medicare patients was Clobetasol Propionate, with 483 prescriptions and refills. In total Jeremy Medler wrote 3,243 Medicare prescriptions that cost $4.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Clobetasol Propionate Generic | 483 | 515 | 247 | $20K |
| Triamcinolone Acetonide Generic | 454 | 550 | 281 | $6,334 |
| Ketoconazole Generic | 239 | 256 | 115 | $2,672 |
| Doxycycline Hyclate Generic | 193 | 367 | 82 | $6,716 |
| Dupixent Pen Dupilumab | 167 | 198 | 36 | $738K |
| Metronidazole Generic | 162 | 167 | 81 | $6,112 |
| Ciclopirox Ciclopirox Olamine | 143 | 155 | 62 | $2,742 |
| Fluorouracil Generic | 139 | 146 | 113 | $7,885 |
| Tacrolimus Generic | 129 | 136 | 69 | $19K |
| Clindamycin Phosphate Generic | 111 | 114 | 47 | $3,268 |
| Hydrocortisone Generic | 110 | 111 | 69 | $534 |
| Dupixent Syringe Dupilumab | 62 | 66 | Under 11 | $245K |
| Taltz Autoinjector Ixekizumab | 62 | 62 | Under 11 | $411K |
| Humira(Cf) Pen Adalimumab | 56 | 56 | Under 11 | $724K |
| Minocycline Hcl Generic | 56 | 56 | 19 | $1,000 |
Brand drugs: 692 claims; generic drugs: 2,551 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Jeremy Medler $3,496 ($3,496 in general payments such as food, travel and fees) from 20 companies. The largest payer was Abbvie Inc. with $559.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 24 | $559 |
| Organon LLC OGN | 14 | $453 |
| Janssen Biotech, Inc. JNJ | 19 | $394 |
| Mayne Pharma Commercial LLC | 12 | $256 |
| UCB, Inc. UCB.BR | 11 | $241 |
| Regeneron Healthcare Solutions, Inc. REGN | 6 | $200 |
| Lilly USA, LLC LLY | 8 | $176 |
| Galderma Laboratories, L.P. GALD.SW | 13 | $152 |
| Novartis Pharmaceuticals Corporation NVS | 5 | $141 |
| Genzyme Corporation SNY | 4 | $140 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.